Reversion of P-Glycoprotein-Mediated Multidrug Resistance in Human Leukemic Cell Line by Carnosic Acid

Xiao-Ning Yu；Xue-Liang Chen；Hao Li；Xiang-Xin Li；Hui-Qing Li；Wen-Rui Jin

carnosic acid ； multidrug resistance ； P-glycoprotein ； reverse

The Chinese Journal of Physiology

51卷6期（2008 / 12 / 01）

348 - 356

英文

One of the common hindrances to successful chemotherapy is the development of multidrug resistance (MDR) by tumor cells to multiple chemotherapeutic agents. In this regard, P-glycoprotein (P-gp) acts as an energized drug pump that reduces the intracellular concentration of drugs, even of structurally unrelated ones. The modulators of P-gp function can restore the sensitivity of MDR cells to anticancer drugs. Therefore, to develop effective drug-resistance-reversing agents, we evaluated the P-gp modulating potential of carnosic acid (CA) in multidrug-resistant K562/AO2 cells in the present study. The reversing effect of CA was evaluated by determining the inhibition rates of cell viability with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) assays. The intracellular adriamycin fluorescence intensity and the expression of P-gp were measured by flow cytometry (FCM). Meanwhile, the subcellular distribution of adriamycin was detected via Laser Scanning Confocal Microscopy (LSCM). The mRNA expression of mdr1was then detected via semiquantitative reverse transcription polymerase chain reaction (RT-PCR). The findings showed that CA decreased apparently the Inhibition Concentration 50% (IC50) of adriamycin by increasing its intracellular concentration and thus enhancing the sensitivity of K562/AO2 cells. Adriamycin was distributed evenly in the cytoplasm when the cells were treated with CA. The expression of mdr1 was decreased. Overall, the results indicated that CA can serve as a novel, non-toxic modulator of MDR, and it can reverse the MDR of K562/AO2 cells in vitro by increasing intracellular adriamycin concentration, down-regulating the expression of mdr1, and inhibiting the function of P-gp.

1. Barrand, M.A.,Rhodes, T.,Center M.S.,Twentyman, P.R.(1993).Chemosensitisation and drug accumulation effects of cyclosporine A, PSC 833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from Pglycoprotein.Eur. J. Cancer,29,408-415.
2. Baylor, S.M.,Hollingworth, S.(2000).Measurement and interpretation of cytoplasmic [Ca2+] signals from calcium-indicator dyes.News Physiol. Sci.,15,19-26.
3. Chen, L.,Xu, X.P.,Wang, J.M.,Fei, X.H.,Gao, L.,Zhou, H.,Huang, Z.X.(2003).Reversal of multidrug resistance in leukemia cell line by cyclosporin a combining with tamoxifen and interferon-α.J. Leukemia Lymphoma,12,135-138.
4. Danilenko, M.,Wang, Q.,Wang, X.,Levy, J.,Sharoni, Y.,Studzinski, G.P.(2003).Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1α,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium.Cancer Res.,63,1325-1332.
5. Danilenko, M.,Wang, X.,Studzinski G.P.(2001).Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.J. Natl. Cancer Inst.,93,1224-1233.
6. Ferlini, C.,Distefano, M.,Pignatelli, F.,Lin, S.,Riva, A.,Bombardelli, E.,Mancuso, S.,Ojima, I.,Scambia, G.(2000).Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.Brit. J. Cancer,83,1762-1768.
7. Fong, W.F.,Wan, C.K.,Zhu, G.Y.,Chattopadhyay, A.,Dey, S.,Zhao, Z.,Shen, X.L.(2007).Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes.Planta Med.,73,212-220.
8. Ford, J.M.(1996).Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.Eur. J. Cancer,32,991-1001.
9. Ford, J.M.,Hait, W.N.(1990).Pharmacology of drugs that alter multidrug resistance in cancer.Pharmacol. Rev.,42,155-199.
10. Gao, F.,Wang, T.,Sheng, M.,Chen, B.,Zhou, Y.,Dong, Y.,Cheng, J.,Zhang, P.(2002).Reversal effect of tetrandrine in combination with droloxifene on cell line K562/A02 and the correlation with apoptosis induction.Zhonghua Xue Ye Xue Za Zhi,12,321-323.
11. Gong, Y.P.,Liu, T.,Jia, Y.Q.,Qin, L.,Deng, C.Q.,Yang, R.Y.(2002).Comparison of P-gp and MRP-mediated multidrug resistance in leukemia cell lines.Int. J. Hematol.,75,154-160.
12. Gong, Y.P.,Wang, Y.T.,Chen, F.Y.,Han, J.Y.,Shao N.X.,Ouyang R.R.(2001).Subcellular distribution of daunorubicin in the Pglycoprotein-mediated multidrug-resistant cell line K562/ADR.Chinese J. Oncol.,23,184-186.
13. Gong, Y.P.,Wang, Y.T.,Chen, F.Y.,Han, J.Y.,Shao, N.X.,Fang, Z.W.,Ouyang, R.R.(2002).Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR.Zhonghua Xue Ye Xue Za Zhi,21,309-311.
14. Hurwitz, S.J.,Terashima, M.,Mizunuma, N.,Slapak, C.A.(1997).Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.Blood,89,3745-3754.
15. Inaba, M.,Fujikura, R.,Tsukagoshi, S.,Sakurai, Y.(1981).Restored in vitro sensitivity of adriamycin-and vincristine-resistant P388 leukemia with reserpine.Biochem. Pharmacol.,30,2191-2194.
16. Larsen, A.K.,Escargueil, A.E.,Skladanowski, A.(2000).Resistance mechanisms associated with altered intracellular distribution of anticancer agents.Pharmacol. Ther.,85,217-229.
17. Lee, J.J.,Jin, Y.R.,Lee, J.H.,Yu, J.Y.,Han, X.H.,Oh, K.W.,Hong, J.T.,Kim, T.J.,Yun, Y.P.(2007).Antiplatelet activity of carnosic acid, a phenolic diterpene from Rosmarinus officinalis.Planta Med.,73,121-127.
18. Li, H.,Chen, X.L.,Li, D.Q.,Zhao, C.L.,Feng, J.B.,Zhang, T.(2006).The influence of arsenic trioxide to HL-60 associated with CA.Zhonghua XueYe Xue Za Zhi,27,194-197.
19. Ling V.(1992).P-glycoprotein and resistance to anticancer drugs.Cancer,69,2693-2609.
20. Lo, A.H.,Liang, Y.C.,Lin-Shiau, S.Y.,Ho, C.T.,Lin, J.K.(2002).Carnosol, an antioxidant in rosemary, suppressed inducible nitric oxide synthase through downregulating nuclear factor-κB in mouse macrophages.Carcinogenesis,23,983-991.
21. Luan, F.J.(1993).Establishment of the multidrug-resistant cell line K562/ A02 and its drug-resistant properties.Zhonghua Zhong Liu Za Zhi,15,101-103.
22. Marks, D.C.,Bebov, L.,Davey, M.W.,Davey, R.A.,Kidman, A.D.(1992).The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells.Leuk. Res.,10,1165-1173.
23. Moreno, S.,Scheyer, T.,Romano, C.S.,Vojnov, A.A.(2006).Antioxidant and antimicrobial activities of rosemary extracts linked to their polyphenol composition.Free Radic. Res.,40,223-231.
24. Moriai, R.,Asanuma, K.,Kobayashi, D.,Yajima, T.,Yagihashi, A.,Yamada, M.(2001).Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells.Anticancer Res.,21,596-600.
25. Offord, E.A.,Mace, K.,Ruffieux, C.,Malnoe, A.,Pfeifer, A.M.(1995).Rosemary components inhibit benzo(a)pyrene-induced genotoxicity in human bronchial cells.Carcinogenesis,16,2057-2062.
26. Oluwatuyi, M.,Kaatz, G.W.,Gibbons, S.(2004).Antibacterial and resistance modifying activity of Rosmarinus officinalis.Phytochemistry,65,3249-3254.
27. Pusztai, L.,Wagner, P.,Ibrahim, N.,Rivera, E.,Theriault, R.,Booser, D.,Symmans, F.W.,Wong, F.,Blumenschein, G.,Fleming, D.R.,Rouzier, R.,Boniface, G.,Hortobagyi, G.N.(2005).Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.Cancer,104,682-691.
28. Sandler, A.,Gordon, M.,De Alwis, D.P.,Pouliquen, I.,Green, L.,Marder, P.,Chaudhary, A.,Fife, K.,Battiato, L.,Sweeney, C.,Jordan, C.,Burgess, M.,Slapak, C.A.(2004).A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979) administered intravenously in combination with doxorubicin in patients with advanced malignancy.Clin. Cancer Res.,10,3265-3272.
29. Sharabani, H.,Izumchenko, E.,Wang, Q.,Kreinin, R.,Steiner, M.,Barvish, Z.(2006).Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.Int. J. Cancer,118,3012-3021.
30. Stewart, A.,Steiner, J.,Mellows, G.,Laguda, B.,Norris, D.,Bevan, P.(2000).Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.Clin. Cancer Res.,6,4186-4191.
31. Visanji, J.M.,Thompson, D.G.,Padfield, P.J.(2006).Induction of G2/M phase cell cycle arrest by carnosol and CA is associated with alteration of cyclin A and cyclin B1 levels.Cancer Lett.,237,130-136.
32. Wan, C.K.,Zhu, G.Y.,Shen, X.L.,Chattopadhyay, A.,Dey, S.,Fong, W.F.(2006).Gomisin A alters substrate interaction and reverses Pglycoprotein-mediated multidrug resistance in HepG2-DR cells.Biochem. Pharmacol.,72,824-837.
33. Wang, Q.,Salman, H.,Danilenko, M.,Studzinski, G.P.(2005).Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK/ AP-1/Egr-1 pathway.J. Cell Physiol.,204,964-974.
34. Willingham, M.C.,Richert, N.D.,Cornwell, M.M.,Tsuruoo, T.,Hamada, H.,Gottesman, M.M.,Pastan, I.H.(1987).Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells.J. Histochem. Cytochem.,35,1451-1456.
35. Wuchter, C.,Leonid, K.,Ruppert, V.,Schrappe, M.,Buchner, T.,Schoch, C.,Haferlach, T.,Harbott, J.,Ratei, R.,Dorken, B.,Ludwig, W.D.(2000).Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.Haematologica,85,711-721.
36. Yang, J.Y.,Luo, H.Y.,Lin, Q.Y.,Liu, Z.M.,Yan, L.N.,Lin, P.,Zhang, J.,Lei, S.(2002).Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.World J. Gastroenterol.,8,644-649.